PET scans could guide smarter breast cancer therapy

NCT ID NCT07527806

Not yet recruiting Disease control Sponsor: Peking University Cancer Hospital & Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a special PET scan (HER2-PET) can help doctors personalize treatment for early-stage HER2-positive breast cancer. After two cycles of standard therapy, the scan results will determine if patients need stronger or milder treatment. The goal is to improve the chance of eliminating the cancer before surgery while avoiding unnecessary side effects. About 156 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Trastuzumab, Pertuzumab, Docetaxel, Nab-paclitaxel, Carboplatin, CDK4/6 inhibitor
What this could lead to: If successful, this could lead to a more personalized treatment approach for HER2-positive breast cancer, potentially improving cure rates and reducing unnecessary side effects.
What could go wrong: This is a Phase 2 trial with only 156 participants, so results may not apply to all patients. The imaging technique is experimental, and the treatment adjustments may not improve outcomes or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.